CN113278552A - Pediococcus acidilactici HG-7 strain and application thereof - Google Patents
Pediococcus acidilactici HG-7 strain and application thereof Download PDFInfo
- Publication number
- CN113278552A CN113278552A CN202110555926.7A CN202110555926A CN113278552A CN 113278552 A CN113278552 A CN 113278552A CN 202110555926 A CN202110555926 A CN 202110555926A CN 113278552 A CN113278552 A CN 113278552A
- Authority
- CN
- China
- Prior art keywords
- pediococcus acidilactici
- cholesterol
- strain
- medicament
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000191998 Pediococcus acidilactici Species 0.000 title claims abstract description 68
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 74
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 36
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 24
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 27
- 239000006041 probiotic Substances 0.000 claims description 21
- 235000018291 probiotics Nutrition 0.000 claims description 21
- 230000000529 probiotic effect Effects 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 18
- 238000002474 experimental method Methods 0.000 abstract description 16
- 230000001603 reducing effect Effects 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 9
- 239000003833 bile salt Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 210000004211 gastric acid Anatomy 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 229920001202 Inulin Polymers 0.000 description 6
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 6
- 229940107187 fructooligosaccharide Drugs 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- 229940029339 inulin Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108010009004 proteose-peptone Proteins 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000001393 triammonium citrate Substances 0.000 description 2
- 235000011046 triammonium citrate Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a Pediococcus acidilactici HG-7 strain and application thereof, wherein the Pediococcus acidilactici HG-7 has been preserved in the China center for type culture Collection at 4 month and 6 days 2021, and the preservation number is CCTCC No. M2021328. The pediococcus acidilactici HG-7 can be used for preparing food for reducing blood fat or medicines for reducing blood fat. The Pediococcus acidilactici HG-7 obtained by screening has better safety, can tolerate gastric acid and bile salt, survive and colonize in intestinal tracts, mediate and improve the intestinal tract micro-ecological balance of hosts, play a beneficial role and generate exact health efficacy; in vitro and animal experiments show that it has strong function of reducing triglyceride and cholesterol in blood.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to a pediococcus acidilactici HG-7 strain and application thereof in regulating blood fat.
Background
Hypercholesterolemia, also known as hyper-and hypo-lipoprotein cholesterolemia, is the leading risk factor for atherosclerotic cardiovascular disease. Recent studies have shown that for every 1mmol/L reduction in low density lipoprotein in populations at risk for various cardiovascular diseases, the major vascular events can be reduced by 21%. According to the statistics of 2013, about 2 hundred million critical hypercholesterolemia people and 8800 ten thousand hypercholesterolemia patients exist in China.
The methods of drug therapy and dietary intervention are mainly used at present to control and reduce blood lipid levels. Statins and fibrates are used in clinic, the curative effect of the drugs in the initial stage is obvious, but side effects with different degrees are generated along with long-term use, so that the health problems of patients are aggravated, for example, myopathy, rhabdomyolysis, abnormal blood sugar, hepatitis, renal dysfunction and the like are easily induced by long-term use of statins, and the liver injury is serious and the risk of gallstones is increased by long-term use of fibrates. The diet of low-fat or low-saturated fat food can effectively reduce the content of cholesterol in serum, but the taste and flavor of the low-fat food are simpler, the diet proposal is not accepted by the public or persisted for a long time, and the diet is easy to rebound after being careless, so that the eating of the functional food for reducing blood fat is a more ideal method for controlling blood fat for a long time.
At present, the research on the blood fat reduction of probiotics lasts for nearly half a century, and two bacterial strains which are deeply researched for the blood fat reduction function in China belong to lactobacillus plantarum, namely L.plantarum P8 and lactobacillus plantarum ST-III. L.plantarum P8 comes from the team of Zhang Ping leading of the university of inner Mongolia agriculture, and animal experiments show that L.plantarum P8 has a remarkable blood lipid reducing effect. The lactobacillus plantarum ST-III researched and developed by a team leading to the university of Kuo and the university of Jiangnan, the general manager of the Ministry of food college of agriculture of northeast China and the Ministry of the Guangming milk industry successfully proves the effect of reducing cholesterol through animal experiments and population clinical experiments, is industrialized, and becomes a probiotic product with independent intellectual property rights of the Ministry of Guangming.
Therefore, the safe and effective lactobacillus with the function of regulating blood fat is developed, and has wide application prospect in the fields of fermented food and medicine.
In view of this, this patent is filed.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a Pediococcus acidilactici HG-7 strain and application thereof, wherein the strain can resist gastric acid and bile salt, survive and colonize in intestinal tracts, mediate and improve the intestinal microecological balance of hosts, regulate blood fat and specifically reduce cholesterol and triglyceride.
The invention aims to provide pediococcus acidilactici HG-7.
Another object of the present invention is to provide the use of Pediococcus acidilactici HG-7 as described above.
According to the Pediococcus acidilactici HG-7 provided by the embodiment of the invention, the preservation number of the Pediococcus acidilactici HG-7 is CCTCC No. M2021328.
The use of Pediococcus acidilactici HG-7 according to a specific embodiment of the present invention in the preparation of a food or a medicament for lowering blood lipid.
Preferably, the food or medicament is a cholesterol and triglyceride lowering food or medicament.
The use of Pediococcus acidilactici HG-7 for the manufacture of a medicament according to an embodiment of the present invention, further comprising said Pediococcus acidilactici HG-7; and a pharmaceutically acceptable non-toxic carrier.
The use of Pediococcus acidilactici HG-7 for preparing a medicament according to an embodiment of the present invention, further, the dosage form of the medicament is selected from at least one of tablets, granules, powders, capsules, suspensions, emulsions and lyophilized preparations; preferably, the medicament is a compound probiotic tablet.
The medicine also comprises pharmaceutically acceptable auxiliary materials. The pharmaceutically acceptable excipients include, but are not limited to: pharmaceutically acceptable carriers, diluents, fillers, binders and other excipients. Such carriers include, but are not limited to, starch or derivatives thereof, lactose, polyethylene glycol; such diluents include, but are not limited to, starch or derivatives thereof, lactose, sucrose, vegetable oils, waxes, fatty acids; fillers include, but are not limited to talc; the adjuvants may also include, for example, preservatives, lubricants, dispersants, flavoring agents, humectants, antioxidants, colorants, stabilizers, buffers, pH adjusters. Such materials may be desirable to aid in the stability of the formulation or to aid in the enhancement of activity or bioavailability or to produce an acceptable mouthfeel or odor upon oral administration.
Use of Pediococcus acidilactici HG-7 according to an embodiment of the present invention for the preparation of a food product, further comprising said Pediococcus acidilactici HG-7, and a bromatologically acceptable additive.
The term "food" as used in the present invention is meant to be understood in a broad sense and may be in any form that can be used, i.e. the food of the present invention may be a health product, a drink, a fermented food, etc. in addition to the conventional forms of food.
Preferably, the food product is a probiotic solid powder. The formulation of a probiotic solid powder will be elucidated in detail in the examples.
According to the application of Pediococcus acidilactici HG-7 in preparing food, furthermore, the probiotic solid powder is prepared from xylooligosaccharide, inulin, fructooligosaccharide, lemon fruit powder and Pediococcus acidilactici HG-7.
According to the application of Pediococcus acidilactici HG-7 in preparing food or medicines, the Pediococcus acidilactici HG-7 is further freeze-dried powder; the freeze-dried powder is prepared by freeze-drying a bacterial suspension of pediococcus acidilactici HG-7 in a freeze dryer under a sterile environment.
Compared with the prior art, the invention has the following beneficial effects:
(1) the Pediococcus acidilactici HG-7 obtained by screening has better safety, can tolerate gastric acid and bile salt, survive and colonize in intestinal tracts, mediate and improve the intestinal tract micro-ecological balance of hosts, play a beneficial role and generate exact health efficacy; in vitro and animal experiments show that it has strong function of reducing triglyceride and cholesterol in blood.
(2) The pediococcus acidilactici HG-7 screened by the method can be used for preparing foods and medicines for reducing cholesterol and triglyceride, and tests show that the obtained foods also have the effects of reducing triglyceride and cholesterol.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 shows the degradation rate of Pediococcus acidilactici HG-7 for cholesterol according to example 2 of the present invention, with the abscissa being the group (blank control, commercial strain, HG-7) and the ordinate being the degradation rate of cholesterol in vitro;
FIG. 2 is a graph showing gastric acid resistance of Pediococcus acidilactici HG-7 according to example 4 of the present invention, with time on the abscissa and viable count of HG-7 strain in simulated gastric fluid at pH 2 on the ordinate;
FIG. 3 is a graph showing bile salt resistance of Pediococcus acidilactici HG-7, in accordance with an embodiment of the present invention, on the abscissa, time, and on the ordinate, OD values of HG-7 strain in MRS medium and MRS medium containing 0.3% bile salt;
FIG. 4 is a graph showing the ability of Pediococcus acidilactici HG-7 to reduce TG levels in vivo, with the abscissa representing the group and the ordinate representing the concentration of triglycerides, according to example 5 of the present invention;
FIG. 5 is a graph showing the ability of Pediococcus acidilactici HG-7 to reduce TC levels in vivo, with the abscissa representing the group and the ordinate representing the concentration of cholesterol, according to an embodiment of the present invention;
FIG. 6 is a graph showing the results of an animal experiment in which probiotic solid powder was used to degrade Triglyceride (TG), according to example 6 of the present invention, the abscissa represents the group and the ordinate represents the concentration of triglyceride;
fig. 7 is a graph showing the results of an animal experiment in which probiotic solid powder degrades cholesterol (TC) according to specific example 6 of the present invention, the abscissa represents the group, and the ordinate represents the concentration of cholesterol.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without any inventive step, are within the scope of the present invention.
The pediococcus acidilactici HG-7 is lactic acid bacteria, can effectively reduce cholesterol and triglyceride, can be used as a component of food and medicines, and can improve the symptoms of hyperlipidemia of a human body.
The new strain Pediococcus acidilactici HG-7 (classification name: Pediococcus acidilactici) is preserved in the China type culture collection at 6 th 4 th 2021, the address of the preservation unit is China, Wuhan university, preserved in the China type culture collection, and the preservation number is CCTCC No. M2021328; viability was tested by the depository at 2021, 4-6 months with the results: and (6) survival.
In some more specific embodiments, the use of Pediococcus acidilactici HG-7 in the manufacture of a food product or a medicament for lowering cholesterol.
Further, the medicine comprises the pediococcus acidilactici HG-7; and a pharmaceutically acceptable non-toxic carrier.
Preferably, the medicament is a compound probiotic tablet.
The food comprises the pediococcus acidilactici HG-7 and a dietetic acceptable additive.
Preferably, the food product is a probiotic solid powder.
Furthermore, the probiotic solid powder is prepared from xylo-oligosaccharide, inulin, fructo-oligosaccharide, lemon fruit powder and pediococcus acidilactici HG-7; the Pediococcus acidilactici HG-7 is freeze-dried powder; the freeze-dried powder is prepared by freeze-drying a bacterial suspension of pediococcus acidilactici HG-7 in a freeze dryer under a sterile environment.
The technical solution of the present invention will be described in further detail below by way of examples with reference to the accompanying drawings. However, the examples are chosen only for the purpose of illustrating the invention and are not to be construed as limiting the scope of the invention.
Example 1 isolation and identification of Pediococcus acidilactici HG-7
1. Culture medium formula optimization
And (3) performing an optimized culture medium experiment in groups to finally obtain the optimal formula of the lactic acid bacteria culture medium:
MRS solid culture medium 1L formula: casein peptone 10.0g/L, beef extract 10.0g/L, yeast extract 5.0g/L, glucose 20.0g/L, dipotassium hydrogen phosphate 2.0g/L, tween 801.0g/L, triammonium citrate 2.0g/L, sodium acetate 5.0g/L, magnesium sulfate 0.1g/L, manganese sulfate 0.05g/L, agar 17.5 g; sterilizing at 121 deg.C for 20min at pH 6.5.
MRS broth culture medium formula: casein peptone 10.0g/L, beef extract 10.0g/L, yeast extract 5.0g/L, glucose 20.0g/L, dipotassium hydrogen phosphate 2.0g/L, tween 801.0g/L, triammonium citrate 2.0g/L, sodium acetate 5.0g/L, magnesium sulfate 0.1g/L, manganese sulfate 0.05g/L, pH6.5, and sterilizing at 121 ℃ for 20 min.
2. Strain screening
The Pediococcus acidilactici HG-7 strain is derived from traditional fermented yoghourt in inner Mongolia, and is obtained by removing the inner Mongolia for sampling and separating from the traditional fermented yoghourt in inner Mongolia. Taking traditional fermented yogurt of inner Mongolia, diluting the sample with sterile normal saline by 10 times gradient to 10-3And coating the lactobacillus strain on an MRS solid culture medium, culturing for 24-48h in an incubator at 37 ℃, observing the morphological characteristics of bacterial colonies, picking suspected bacterial colonies of lactobacillus on the MRS solid culture medium, respectively transferring the suspected bacterial colonies to an MRS liquid culture medium for pure culture, totally separating 8 strains, and numbering each strain.
The acid and cholate tolerance and the cholesterol-reducing ability of the strains of bacteria obtained by separation and purification are measured, the detailed experimental steps are shown in example 2 and example 3, and the pediococcus acidilactici HG-7 with strong acid and cholate tolerance and strong cholesterol-reducing ability is obtained by screening.
3. Strain identification
Extracting total bacterial DNA from the screened Pediococcus acidilactici HG-7, and carrying out 16s rDNA amplification, wherein the primers are as follows:
sgF:5'-AGAGTTTGATCATGGCTCAG-3'(SEQ ID NO：1)
sgR:5'-TAGGGTTACCTTGTTACGACTT-3'(SEQ ID NO：2)
the primers are used for PCR amplification and agarose gel electrophoresis, and then gel cutting, recovery and sequencing are carried out.
The sequencing result of the 16s DNA of the strain obtained by separation is shown as SEQ ID NO. 3.
Example 2 in vitro cholesterol removal assay of Pediococcus acidilactici HG-7
The in vitro cholesterol removal rate of the strain is detected according to the following steps, and a commercial strain lactobacillus plantarum 299V is taken as an experimental control group, and the method specifically comprises the following steps:
transferring the test strain into MRS liquid culture medium, culturing at 37 deg.C for 24h, subculturing for 2 times with 1% inoculum size, and culturing at 37 deg.C for 15 h. Preparing a liquid MRS culture medium, and sterilizing for later use;
preparing an MRS medium (culture solution MRSO-CHOL) containing cholesterol: the medium consists of MRS liquid medium, sodium thioglycollate, bile salt and cholesterol, wherein the concentration of the sodium thioglycollate in the culture solution MRSO-CHOL is 2g/L, the concentration of the bile salt in the culture solution MRSO-CHOL is 0.3%, and the concentration of the cholesterol is 120 ug/ml.
Experimental groups: the activated pediococcus acidilactici HG-7 bacterial liquid is inoculated into 10ml of culture solution MRSO-CHOL according to the inoculation amount of 1%.
Positive control group: the bacterial solution of the activated commercial strain was inoculated in 10ml of the culture solution MRSO-CHOL at an inoculum size of 1%.
Blank control group: 10ml of the culture broth MRSO-CHOL without the inoculated strain.
Placing the two groups of samples in a constant-temperature incubator at 37 ℃ for 24h, taking out and shaking up, centrifuging for 15min at 4000r/m, taking supernatant, measuring the content of cholesterol in the supernatant by using an o-phthalaldehyde color developing agent, and calculating the removal rate of the cholesterol.
Wherein, the cholesterol removal rate is the difference between the cholesterol of the control group and the cholesterol of the experimental group/the cholesterol content of the control group.
The experimental result is shown in figure 1, the cholesterol reduction rate of the pediococcus acidilactici HG-7 is 73.75%, which indicates that the pediococcus acidilactici HG-7 has stronger in vitro cholesterol reduction capability.
Example 3 bacterial safety test of Pediococcus acidilactici HG-7
(1) Antibiotic susceptibility testing
HG-7 antibiotic resistance was tested by microdilution. Test antibacterial drugs (Gentamicin, Kanamycin, Tetracycline, Erythromycin, Clindamycin, Chloramphenicol, Amplicilin, the initial concentrations of which are 1024ug/ml, 256ug/ml, 64ug/ml, 8ug/ml, 16ug/ml, 64ug/ml and 16ug/ml) are diluted for 12 times in a series of ratios, the diluted test bacterial liquid in 2ml is added into corresponding holes of a 96-well plate respectively, the test bacterial liquid is cultured for 48 hours and observed, and the test bacterial liquid is the Minimum Inhibitory Concentration (MIC) hole of the antibacterial drugs, namely the sensitivity of the test strain. The results of the experiment are shown in table 1:
TABLE 1 resistance test results of Pediococcus acidilactici HG-7 to antibiotics
As can be seen from Table 1, the results of the antibiotic resistance test of Pediococcus acidilactici HG-7 indicate that the MIC of the antibiotic is within a safe range.
(2) Metabolite toxicity detection
And (3) detecting the optical activity of the lactic acid: the detection was carried out using D-/L-lactic acid detection kit from Megazyme of Ireland. The experimental result shows that D-lactic acid is not produced.
Nitrate reductase activity assay: under aseptic conditions, inoculating the activated strain into a nitrate culture medium according to the inoculation amount of 3 percent, culturing for 5 days at 37 ℃, dropwise adding 10 drops of potassium iodide solution and 10 drops of starch solution respectively, and observing the experimental result. And simultaneously, carrying out a blank experiment. The experimental results show that all bacteria liquid are not changed into blue, and the bacteria liquid is negative reaction.
Indole experiments: under the aseptic condition, the activated strain is inoculated into peptone water nutrient medium according to 3 percent of inoculation amount. Culturing at 37 ℃ for 72h, adding 8-10 drops of indole reagent, and observing the experimental result. And simultaneously, carrying out a blank experiment. The experimental result shows that red rings do not appear, and the metabolism does not produce indole.
Detecting the activity of amino decarboxylase: bacteria having an amino acid decarboxylase decompose an amino acid to decarboxylate the amino acid to produce an amine (lysine → cadaverine, ornithine → putrescine, arginine → spermine) and carbon dioxide, make the medium alkaline, and drop-add an indicator (bromocresol purple), which is yellow negative and purple positive. The experimental results showed that the assay tube was yellow and negative.
(3) The strain is extracted with plasmid, and HG-7 is not found to carry any plasmid, which indicates that the strain has no possibility of gene level transfer.
(3) Determination of cell adhesion Capacity
Culturing the cell monolayer culture in the 6-well plate for 1h at the constant temperature of 37 ℃ by using incomplete DMEM (without serum and double antibody); sucking out the culture solution, washing with sterile PBS for 3 times, and sucking the washing solution to dry; 500. mu.L of 10 was taken8Uniformly mixing cfu/mL experimental strains with 500 mu L incomplete DMEM, adding the mixture into a 6-hole culture plate, setting a blank control of only bacteria liquid without cells, and culturing at 37 ℃ for 1.5h at constant temperature; taking out the culture plate, sucking the culture solution to dry, washing with sterile PBS for 5 times, and sucking the washing solution to dry; adding 10% of formaldehyde into each hole, and fixing for 2 hours at room temperature; sucking dry the stationary liquid, washing for 3 times by sterile PBS, sucking dry the washing liquid, and drying at room temperature; microscopic examination after gram staining, randomly selecting 20 fields for counting, and calculating the adhesion index:
adhesion index-number of bacteria per cell (i.e.average number of bacteria adhered per cell)
The strains randomly select 20 fields, count the total number of bacteria adhered to the cells in the fields and the number of the cells and determine an adhesion index, and the experimental result is as follows: HG-7 has an HT-29 adhesion index of 5.7 for human colon cancer cell lines, is equivalent to that of a control Lactobacillus casei 334 strain, and has better cell adhesion capacity.
EXAMPLE 4 in vitro acid and bile resistance assay of Pediococcus acidilactici HG-7
Preparing simulated gastric fluid SGF (2.0g NaCl, 3.2g pepsin (pepsin) and a proper amount of concentrated hydrochloric acid to adjust the pH value to 3.0), and filtering the mixture by using a 0.2 mu m microporous membrane for later use. Selecting slant strains to be cultured in an MRS liquid culture medium for 16-18 h at 37 ℃. Centrifuging the bacterial suspension at 4000r/min for 15min, removing supernatant, weighing wet weight of the bacterial strain, suspending the bacterial strain in physiological saline according to the weight ratio of 0.1g/ml, and adding the bacterial strain into the saline according to the weight ratio of 1: adding the mixture of 10 into SGF solution, mixing uniformly, culturing in a constant temperature incubator at 37 ℃ for 2h, and counting cells. The experimental result is shown in figure 2, the number of the viable bacteria is kept at an order of magnitude, and the strong acid resistance of Pediococcus acidilactici HG-7 in vitro is shown.
The twice activated bacterial liquid is inoculated into 10mL MRS liquid culture medium containing 0.3% cholate according to the amount of 1% for culture and growth curve determination, and the experimental result is shown in figure 3, which shows that HG-7 has stronger bile resistance in vitro.
Example 5 in vivo efficacy Studies of Pediococcus acidilactici HG-7 (animal experiments)
(1) Preparation of the experimental strains:
inoculating activated Pediococcus acidilactici HG-7 into MRS liquid culture medium, culturing at 37 deg.C for 18h, centrifuging at 6000r/m for 10min, washing with sterilized normal saline, and collecting thallus. Then, 0.85% physiological saline was added to adjust the number of bacteria to about 1.0X 109CFU/ml, then subpackaging viable bacteria into 15ml centrifuge tubes according to daily dosage, taking dosage of 2 ml/each daily, 10 each group, and 4 groups, and requiring intragastric administration for 28 days.
(2) Grouping and feeding modes of experimental animals:
Sprague-Dawley line 5 week old male rats, 40 in total, were freely fed to day 28, and were divided on average into 4 groups of 10 animals per group:
HG-7 group: feeding live bacteria suspension for intragastric administration with high-fat feed;
model group: intragastric feeding 0.85% normal saline, and feeding high fat feed;
normal group: gavage 0.85% normal saline, and feeding standard feed;
blood fat recovery group: gavage a standard dose of Xuezhikang, and feeding high-fat feed.
Each 2ml of the mixture is infused in the stomach for 28 days every day, and then the infusion is stopped, and the feed and water of each group are unchanged for 28 days.
(3) Sample collection and analytical testing:
blood was collected before the official test, on day 28 and at time intervals. The blood collection method comprises collecting blood in femoral vein of rat after eating overnight, centrifuging at 4000r/m for 10min after blood coagulation, separating serum by using kit (name: total cholesterol determination kit, company: Ou diagnosis products Co., Ltd., Jiang Dong, Zhe) and color-changing acid color development method, enzyme labeling instrument (company: molecular Devices, model: spectra MAX190) were tested for cholesterol and triglycerides, respectively.
(4) Results of the experiment
The results of the experiment are shown in FIGS. 4 and 5. After the rat is fed with the bacterial suspension containing the HG-7 strain for 28 days, femoral vein blood drawing tests show that Triglyceride (TG) and cholesterol (TC) in the rat blood are respectively reduced by 20.0% and 28.7% compared with a control, which indicates that pediococcus acidilactici HG-7 has the effect of reducing cholesterol and triglyceride in the rat body.
EXAMPLE 6 preparation of probiotic solid powder
A method for preparing composite probiotic solid powder for regulating blood lipid is provided. The paint comprises the following components in percentage by weight: 30% of lemon fruit powder, 22% of fructo-oligosaccharide, 20% of xylo-oligosaccharide, 20% of inulin and 8% of pediococcus acidilactici HG-7 bacterial powder.
Animal experiments prove that the Pediococcus acidilactici HG-7 effectively reduces the levels of cholesterol and triglyceride in serum. The fructo-oligosaccharide, xylo-oligosaccharide and inulin are prebiotics and can promote the proliferation of probiotics. In addition, various studies at home and abroad show that fructo-oligosaccharide, xylo-oligosaccharide and inulin can reduce the concentration of triglyceride and cholesterol in serum, thereby improving lipid metabolism. The formula also has the advantages of natural components, scientific formula, balanced nutrition, convenient taking, good solubility and no sticking to teeth.
The composite probiotic solid powder is prepared by the following process steps:
(1) freeze-drying powder preparation: by freeze-dryingFreeze vacuum drying the bacterial suspension of Pediococcus acidilactici HG-7 in sterile environment to obtain Pediococcus acidilactici HG-7 lyophilized powder with vacuum degree of 6Pa, freezing temperature of-40 deg.C, and lyophilizing time of
And (4) hours. Wherein the viable count of each gram of Pediococcus acidilactici HG-7 lyophilized powder is 3 × 1011cfu, the water content is less than 5%;
(2) preparing materials: transferring Pediococcus acidilactici HG-7, lemon fruit powder, fructo-oligosaccharide, xylo-oligosaccharide, inulin and raw materials into a 10 ten thousand grade clean area, sampling and inspecting;
(3) sieving: after the inspection is qualified, respectively sieving the raw materials by a 80-mesh sieve, and weighing the raw materials according to the proportion;
(4) mixing: mixing the weighed raw materials while stirring, and mixing to obtain a mixed powder with consistent color and no color difference;
(5) packaging: and packaging the mixed powder according to the measured weight, labeling and boxing to obtain a finished product.
The compound probiotic solid powder for regulating blood fat obtained in example 6 is subjected to a pharmacodynamic test scheme: experimental protocol As in example 5, the intragastric sample was changed to a suspension prepared by adding sterile water to the probiotic solid powder, and the number of bacteria was adjusted to about 1X 109CFU/mL, the dose is 2 mL/mouse per day.
After the high-fat rats are fed with the suspension of the probiotic solid powder for 28 days, femoral vein blood drawing detection shows that the results are shown in fig. 6 and 7, and the results show that compared with a control, triglyceride and cholesterol in the blood of the rats are obviously reduced, pediococcus acidilactici HG-7 is fixedly planted in the rats and plays a role, and the probiotic solid powder for intragastric administration has the effect of reducing triglyceride and cholesterol in the rats.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
SEQUENCE LISTING
<110> Shenzhen Shenhua Dai agricultural application research institute
<120> Pediococcus acidilactici HG-7 strain and application thereof
<130> 202104
<160> 3
<170> PatentIn version 3.3
<210> 1
<211> 20
<212> DNA
<213> unknown
<400> 1
<210> 2
<211> 22
<212> DNA
<213> unknown
<400> 2
tagggttacc ttgttacgac tt 22
<210> 3
<211> 1264
<212> DNA
<213> unknown
<400> 3
gcgtgagtga agaagggttt cggctccgta aagctctgtt gttaaagaag aacgtgggtg 60
agagtaactg ttcacccagt gacggtattt aaccagaaag ccacggctaa ctacgtgcca 120
gcagccgcgg taatacgtag gtggcaagcg ttatccggat ttattgggcg taaagcgagc 180
gcaggcggtc ttttaagtct aatgtgaaag ccttcggctc aaccgaagaa gtgcattgga 240
aactgggaga cttgagtgca gaagaggaca gtggaactcc atgtgtagcg gtgaaatgcg 300
tagatatatg gaagaacacc agtggcgaag gcggctgtct ggtctgtaac tgacgctgag 360
gctcgaaagc atgggtagcg aacaggatta gataccctgg tagtccatgc cgtaaacgat 420
gattactaag tgttggaggg tttccgccct tcagtgctgc agctaacgca ttaagtaatc 480
cgcctgggga gtacgaccgc aaggttgaaa ctcaaaagaa ttgacggggg cccgcacaag 540
cggtggagca tgtggtttaa ttcgaagcta cgcgaagaac cttaccaggt cttgacatct 600
tctgccaacc taagagatta ggcgttccct tctctgatgg agcaacgccg cgtgagtgaa 660
gaagggtttc ggctcgtaaa gctctgttgt taaagaagaa cgtgggtgag agtaactgtt 720
cacccagtga cggtatttaa ccagaaagcc acggctaact acgtgccagc agccgcggta 780
atacgtaggt ggcaagcgtt atccggattt attgggcgta aagcgagcgc aggcggtctt 840
ttaagtctaa tgtgaaagcc ttcggctcaa ccgaagaagt gcattggaaa ctgggagact 900
tgagtgcaga agaggacagt ggaactccat gtgtagcggt gaaatgcgta gatatatgga 960
agaacaccag tggcgaaggc ggctgtctgg tctgtaactg acgctgaggc tcgaaagcat 1020
gggtagcgaa caggattaga taccctggta gtccatgccg taaacgatga ttactaagtg 1080
ttggagggtt tccgcccttc agtgctgcag ctaacgcatt aagtaatccg cctggggagt 1140
acgaccgcaa ggttgaaact caaaagaatt gacgggggcc cgcacaagcg gtggagcatg 1200
tggtttaatt cgaagctacg cgaagaacct taccaggtct tgacatcttc tgccaaccta 1260
agag 1264
Claims (6)
1. The Pediococcus acidilactici HG-7 is characterized in that the preservation number of the Pediococcus acidilactici HG-7 is CCTCC No. M2021328.
2. Use of Pediococcus acidilactici HG-7 according to claim 1 in the preparation of a food product or a medicament.
3. The use according to claim 2, wherein the food or medicament is a hypolipidemic food or hypolipidemic medicament; preferably, the food or medicament acts to reduce cholesterol or to reduce triglycerides.
4. The use according to claim 3, wherein the medicament comprises Pediococcus acidilactici HG-7 of claim 1; and a pharmaceutically acceptable non-toxic carrier.
5. The use of claim 4, wherein the medicament is in a dosage form selected from at least one of tablets, granules, powders, capsules, suspensions, emulsions, lyophilized formulations; preferably, the medicament is a compound probiotic tablet.
6. Use according to claim 3, wherein the food product comprises Pediococcus acidilactici HG-7 according to claim 1, and a bromatologically acceptable additive; preferably, the food product is a probiotic solid powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110555926.7A CN113278552A (en) | 2021-05-21 | 2021-05-21 | Pediococcus acidilactici HG-7 strain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110555926.7A CN113278552A (en) | 2021-05-21 | 2021-05-21 | Pediococcus acidilactici HG-7 strain and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113278552A true CN113278552A (en) | 2021-08-20 |
Family
ID=77280564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110555926.7A Pending CN113278552A (en) | 2021-05-21 | 2021-05-21 | Pediococcus acidilactici HG-7 strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113278552A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115191607A (en) * | 2022-05-10 | 2022-10-18 | 珠海益何生物技术有限公司 | Lactobacillus plantarum YU28 strain and application thereof |
| CN115337327A (en) * | 2022-08-12 | 2022-11-15 | 南京农业大学 | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions |
| WO2023221410A1 (en) * | 2022-05-16 | 2023-11-23 | 苏州普瑞森生物科技有限公司 | Separation and use of strain having anti-cancer effect |
| CN117866844A (en) * | 2024-01-18 | 2024-04-12 | 朗恒科技集团有限公司 | Pediococcus acidilactici LH01 and application thereof |
| CN115337327B (en) * | 2022-08-12 | 2024-07-02 | 南京农业大学 | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883995A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus acidilactici JQII-5 bacterial strains and application thereof |
| CN107691937A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of vegetable protein beverage and preparation method thereof |
| CN107693547A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of Preparation method and use of probiotic composition |
| CN109182225A (en) * | 2018-10-30 | 2019-01-11 | 吉林省农业科学院 | One plant of Pediococcus acidilactici and its application in antiatherosclerosis |
-
2021
- 2021-05-21 CN CN202110555926.7A patent/CN113278552A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106883995A (en) * | 2015-12-16 | 2017-06-23 | 深圳华大农业与循环经济科技有限公司 | Pediococcus acidilactici JQII-5 bacterial strains and application thereof |
| CN107691937A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of vegetable protein beverage and preparation method thereof |
| CN107693547A (en) * | 2016-08-09 | 2018-02-16 | 深圳华大三生园科技有限公司 | A kind of Preparation method and use of probiotic composition |
| CN109182225A (en) * | 2018-10-30 | 2019-01-11 | 吉林省农业科学院 | One plant of Pediococcus acidilactici and its application in antiatherosclerosis |
Non-Patent Citations (3)
| Title |
|---|
| CHENG-CHIH TSAI ET AL.: "Cholesterol-Lowering Potentials of Lactic Acid Bacteria Based on Bile-Salt Hydrolase Activity and Effect of Potent Strains on Cholesterol Metabolism In Vitro and In Vivo", 《THE SCIENTIFIC WORLD JOURNAL》 * |
| 彭灿等: "降胆固醇乳酸菌的筛选和分析比较", 《中国微生态学杂志》 * |
| 王辑 等: "内蒙古奶豆腐中潜在益生性乳酸菌的筛选", 《食品科学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115191607A (en) * | 2022-05-10 | 2022-10-18 | 珠海益何生物技术有限公司 | Lactobacillus plantarum YU28 strain and application thereof |
| WO2023221410A1 (en) * | 2022-05-16 | 2023-11-23 | 苏州普瑞森生物科技有限公司 | Separation and use of strain having anti-cancer effect |
| CN115337327A (en) * | 2022-08-12 | 2022-11-15 | 南京农业大学 | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions |
| CN115337327B (en) * | 2022-08-12 | 2024-07-02 | 南京农业大学 | Preparation method and application of probiotic preparation with lipid-lowering, anti-inflammatory and antioxidant functions |
| CN117866844A (en) * | 2024-01-18 | 2024-04-12 | 朗恒科技集团有限公司 | Pediococcus acidilactici LH01 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113403219A (en) | Lactobacillus plantarum HG-23 strain and application thereof | |
| CN113388540A (en) | Pediococcus pentosaceus HG-9 strain and application thereof | |
| CN110964655B (en) | Bifidobacterium lactis BL-99 and application thereof | |
| CN109810912B (en) | Lactobacillus plantarum LH-511 and application thereof | |
| CN110964653B (en) | Lactobacillus paracasei ET-22 capable of adjusting intestinal flora balance | |
| CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN108004155A (en) | Lactobacillus plantarum pc-26 bacterial strains and its application | |
| CN109810913B (en) | Lactobacillus rhamnosus ASD-9 and application thereof | |
| CN113278552A (en) | Pediococcus acidilactici HG-7 strain and application thereof | |
| CN112625979B (en) | Lactobacillus casei for resisting helicobacter pylori and application thereof | |
| CN107287133A (en) | One lactobacillus plantarum LLY 606 and its application | |
| CN106883995A (en) | Pediococcus acidilactici JQII-5 bacterial strains and application thereof | |
| CN111925961A (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN112057479B (en) | Probiotic composition capable of relieving diarrhea caused by antibiotics | |
| CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
| CN110522035A (en) | A kind of humanized's probiotics and its application in terms of assisting in reducing blood sugar | |
| CN113122478A (en) | Lactobacillus paracasei capable of relieving gastrointestinal injury caused by capsaicin and application thereof | |
| CN114214230B (en) | Lactobacillus North with helicobacter pylori copolymerization capability and application thereof | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN111000244A (en) | Lactobacillus casei capable of improving intestinal health and application thereof | |
| CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
| CN116200290A (en) | Lactobacillus paracasei capable of inhibiting proliferation of colorectal cancer cells and application thereof | |
| US9272007B2 (en) | Strain of L. bulgaricus capable of inhibiting the adhesion of H. pylori strains to epithelial cells | |
| US20220347238A1 (en) | Lactic acid bacteria composition for reducing fat and promoting exercise performance and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210820 |
|
| RJ01 | Rejection of invention patent application after publication |